Your search returned 3 results.

Results
	1.	Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR [electronic resource] by Musolino, Antonino Campone, Mario Neven, Patrick Denduluri, Neelima Barrios, Carlos H Cortes, Javier Blackwell, Kimberly Soliman, Hatem Kahan, Zsuzsanna Bonnefoi, Hervé Squires, Matthew Zhang, Yong Deudon, Stephanie Shi, Michael M André, Fabrice Producer: 20170807 In: Breast cancer research : BCR vol. 19 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. [electronic resource] by André, Fabrice Bachelot, Thomas Campone, Mario Dalenc, Florence Perez-Garcia, Jose M Hurvitz, Sara A Turner, Nicholas Rugo, Hope Smith, John W Deudon, Stephanie Shi, Michael Zhang, Yong Kay, Andrea Porta, Diana Graus Yovine, Alejandro Baselga, José Producer: 20140128 In: Clinical cancer research : an official journal of the American Association for Cancer Research vol. 19 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. [electronic resource] by Shaw, Alice T Kim, Tae Min Crinò, Lucio Gridelli, Cesare Kiura, Katsuyuki Liu, Geoffrey Novello, Silvia Bearz, Alessandra Gautschi, Oliver Mok, Tony Nishio, Makoto Scagliotti, Giorgio Spigel, David R Deudon, Stéphanie Zheng, Cheng Pantano, Serafino Urban, Patrick Massacesi, Cristian Viraswami-Appanna, Kalyanee Felip, Enriqueta Producer: 20170911 In: The Lancet. Oncology vol. 18 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)